Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Aug 11, 2020 · 10-Q · 42 days after period end · 0001564590-20-039121
| Metric | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|
| Revenue | $2.00M | — | — |
| Net Income | -$15.69M | -$13.17M | -$7.85M |
| EPS Diluted | -$0.66 | -$9.21 | -$7.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 11, 2020 · 42 d after period end
